In the SURPASS-2 trial published in the New England Journal of Medicine, participants treated with tirzepatide (5 mg, 10 mg, or 15 mg weekly) experienced reductions in fasting triglycerides from baseline over 40 weeks, with greater reductions generally seen at higher doses
NLRP3, NOD-like receptor pyrin domain-containing protein 3
This class of drugs was first used to treat type 2 diabetes
doi:10.23736/S2724-6507.22.03752-6 Abuqwider JN, Mauriello G, Altamimi M
Always consult a healthcare provider before starting Contrave to ensure it is safe for you
As previously mentioned, early studies using direct measurements in muscle after 14 days on 4 to 6 g of carnitine per day failed to show increases in the muscle carnitine concentration (4, 5)